Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
3/23/2026, 12:00:00 AM
Pfizer and Valneva announced positive topline results from the Phase 3 trial of their Lyme disease vaccine candidate (PF-07307405), showing over 70% efficacy. Pfizer plans to submit for regulatory approval in 2026. Medium importance estimated due to positive Phase 3 results for a key vaccine candidate.
Korean Translation
화이자와 발네바, 라임병 백신 후보물질(PF-07307405)의 3상 임상시험에서 70% 이상의 효능을 보인 긍정적인 탑라인 결과를 발표함. 2026년 규제 당국에 승인을 신청할 계획임. 주요 백신 후보물질의 3상 성공으로 인해 중간 중요도로 예상됨.
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
CME Group Inc (CME) · Other
CME Group will expand regulated cryptocurrency futures and options trading to 24/7 starting on 2026-05-29, pending regulatory review, scheduled.
5/29/2026, 12:00:00 AM
Dell Technologies Inc (DELL) · Earnings Release
Dell Technologies is scheduled to report its fiscal Q1 2027 earnings on May 28, 2026. Since earnings reports typically drive price movements exceeding 5%, significant volatility is scheduled.
5/28/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA PDUFA action date for the subcutaneous formulation of LEQEMBI for treatment initiation in early Alzheimer's disease is scheduled. This regulatory milestone is estimated to have a medium impact on stock price.
5/24/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
ONEOK 2026 annual meeting of shareholders on May 20, 2026, is estimated to have a price impact of at least 1% and is scheduled.
5/20/2026, 12:00:00 AM
Keysight Technologies Inc (KEYS) · Earnings Release
Keysight Technologies' fiscal second-quarter 2026 earnings report is scheduled for May 19, 2026; a price movement of 5% or more is expected.
5/19/2026, 12:00:00 AM